Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib

Kazuko Sakai; Haruhiko Takeda; Norihiro Nishijima; Etsuro Orito; Kouji Joko; Yasushi Uchida; Namiki Izumi; Kazuto Nishio; Yukio Osaki

doi:10.18632/oncotarget.4270

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib

Kazuko Sakai _, Haruhiko Takeda, Norihiro Nishijima, Etsuro Orito, Kouji Joko, Yasushi Uchida, Namiki Izumi, Kazuto Nishio and Yukio Osaki

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:21636-21644. https://doi.org/10.18632/oncotarget.4270

Metrics: PDF 2492 views | HTML 3505 views | ?

Abstract

Kazuko Sakai1,*, Haruhiko Takeda2,7,*, Norihiro Nishijima2, Etsuro Orito3, Kouji Joko4, Yasushi Uchida5, Namiki Izumi6, Kazuto Nishio1 and Yukio Osaki2

1 Department of Genome Biology, Kinki University Faculty of Medicine, Ohono-Higashi, Osaka-Sayamashi, Osaka, Japan

2 Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan

3 Department of Gastroenterology and Hepatology, Nagoya Daini Red Cross Hospital, Nagoya City, Japan

4 Center for Liver-Biliary-Pancreatic Diseases, Matsuyama Red Cross Hospital, Matsuyama City, Japan

5 Department of Gastroenterology, Matsue Red Cross Hospital, Matsue City, Japan

6 Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Japan

7 Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Shogoin-Kawaharacho, Kyoto, Japan

* These authors have contributed equally to this work

Correspondence to:

Kazuto Nishio, email:

Keywords: hepatocellular cancer, sorafenib, response, mutation

Received: March 05, 2015 Accepted: May 08, 2015 Published: May 25, 2015

Abstract

The multi-kinase inhibitor sorafenib is now used as standard therapy for advanced hepatocellular carcinoma (HCC). Predictive biomarkers of response to sorafenib are thus necessary. The purpose of this study was to assess the feasibility of using targeted DNA and RNA sequencing to elucidate candidate biomarkers of sorafenib response using fine-needle biopsy, formalin-fixed paraffin-embedded (FFPE) specimens in patients with HCC. Targeted DNA and RNA deep sequencing were feasible for the evaluation of fine-needle biopsy FFPE specimens obtained from 46 patients with HCC treated with sorafenib. Frequent mutations of suppressor genes, such as CTNNB1 (34.8%) and TP53 (26.1%), were detected in the HCC tumors. After excluding these suppressor genes, the average numbers of detected oncogene mutations differed significantly between the non-PD and PD groups (P = 0.0446). This result suggests that the oncogene mutational burden in the tumor might be associated with the clinical response to sorafenib. We have identified candidate gene expression (TGFa, PECAM1, and NRG1) in tumor for the prediction of sorafenib response and PFS by RNA sequencing. Our findings provide new insights into biomarkers for sorafenib therapy and allow us to discuss future therapeutic strategies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4270

Publication Alerts

Research Papers:

Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib

Abstract